Shaping the future of AFib care, together.
FARAWATCH unites the FARAPULSE PFA Platform and WATCHMAN FLX Pro in one coordinated case. The OPAL HDx™ Mapping System provides visualization for integrated mapping and ablation confirmation, while the WATCHMAN TruSteer™ Access System supports implant delivery with precision steering. Together, these technologies help physicians move through each step with greater continuity and control.
One proven workflow. One coordinated case, from access to closure.
Explore the comprehensive concomitant workflow; a unified procedural pathway for AFib care and stroke protection.
Two category leaders. One concomitant approach.
Discover our solutions for your concomitant PFA + LAAC needs
Related products
Clinically Proven
Real-world results demonstrated a strong safety profile and high LAA closure, supporting FARAWATCH — a concomitant FARAWAVE PFA and WATCHMAN FLX Pro procedure, as a practical approach for AFib patients eligible for both therapies.
Peer Perspectives: Case Insights
Clinicians highlight workflow best practices, clinical evidence, and patient benefit of combining FARAPULSE PFA and WATCHMAN FLX Pro procedures in one streamlined case.
FARAWATCH Resources
Find the resources you need to support your practice, increase efficiencies, improve patient outcomes, and transform a concomitant procedure into a more complete model of AFib care.
† MAE data reflect outcomes from a real-world registry. SAE rate of 2.1% observed in the ADVENT Pivotal Trial evaluating the FARAPULSE™ Pulsed Field Ablation System. Source: Reddy, Vivek Y., et al. “Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation.” New England Journal of Medicine 389.18 (2023): 1660-1671.
References
- Ekanem E, Reddy VY, et al. Multi-National Survey on the Safety of the post-approval clinical use of Pulsed Field Ablation in 17,000 + patients (MANI FEST 17K)
*Defined as the occurrence of death, stroke, esophageal fistula or dysmotility, pulmonary vein stenosis, persistent phrenic nerve injury, pericardial tamponade, vascular complication, coronary artery spasm, hemolysis, or thrombosis - Piccini et al. Poster Presentation. HRS 2 025.
*Defined as the occurrence of all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention between device implantation and seven days or hospital discharge (whichever is later). Includes device or procedure related events requiring open cardiac surgery or major endovascular intervention such as pseudoaneurysm repair, AV fistula repair, or other major endovascular repair. - Wazni O, et al. New England Journal of Medicine, November 2024 . Primary Efficacy: Stroke, mortality, systemic embolism. Primary Safety: Non-procedural ISTH major and clinically-relevant non-major bleeding
- Eckart R, et al. Heart Rhythm O2. 2025;In-Press:1-8. doi:10.1016/j.hroo.2025.07.014
- Saliba W, et al. Heart Rhythm Journal, May 2025.
- Huded, c. et al. Procedure Characteristics and Early Clinical Outcomes of Left Atrial Appendage Occlusion Using a Novel SteerableAccess System: A Sub-analysis of HEAL-LAA. NY Heart Valves 2025